Table I.
Patient population.
| Tumors | N | % |
|---|---|---|
| Histological type | 204 | 100 |
| IDC | 131 | 64.2 |
| ILC | 27 | 13.2 |
| DCIS | 30 | 14.7 |
| Other | 16 | 7.8 |
| SBR grade | 174 | 100 |
| 1 | 39 | 22.4 |
| 2 | 98 | 56.3 |
| 3 | 37 | 21.3 |
| TNM classification | 166 | 100 |
| T | 13 | 7.5 |
| T0-T1a | 42 | 24.1 |
| T1b | 65 | 37.4 |
| T1c | 43 | 24.7 |
| T2 | 3 | 1.7 |
| T3 | ||
| TNM classification | 204 | 100 |
| N | 112 | 54.9 |
| NO | 59 | 28.9 |
| N1 | 4 | 1.9 |
| N2 | 8 | 3.9 |
| N3 | 21 | 10.3 |
| Nx | ||
| Hormonal receptor | 204 | 100 |
| HR+ | 175 | 85.8 |
| HR− | 26 | 12.7 |
| UK | 3 | 1.5 |
| HER2 status | 174 | 100 |
| Negative | 151 | 86.8 |
| Positive | 20 | 11.5 |
| Unknown | 3 | 1.7 |
| Triple negative | 13/174 | 7.5 |
DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; HR, hormonal receptor; TNM, Tumor node metastasis; SBR, Scarf-Bloom-Richardson.